S
Seiji Isonishi
Researcher at Jikei University School of Medicine
Publications - 84
Citations - 2636
Seiji Isonishi is an academic researcher from Jikei University School of Medicine. The author has contributed to research in topics: Ovarian cancer & Carboplatin. The author has an hindex of 21, co-authored 83 publications receiving 2412 citations.
Papers
More filters
Journal ArticleDOI
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata,Makoto Yasuda,Fumiaki Takahashi,Seiji Isonishi,Toshiko Jobo,Daisuke Aoki,Hiroshi Tsuda,Toru Sugiyama,Shoji Kodama,Eizo Kimura,Kazunori Ochiai,Kiichiro Noda +11 more
TL;DR: Dose-dense weekly paclitaxel plus carboplatin improved survival compared with the conventional regimen and represents a new treatment option in women with advanced epithelial ovarian cancer.
Journal ArticleDOI
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata,Makoto Yasuda,Seiji Isonishi,Fumiaki Takahashi,Hirofumi Michimae,Eizo Kimura,Daisuke Aoki,Toshiko Jobo,Shoji Kodama,Fumitoshi Terauchi,Toru Sugiyama,Kazunori Ochiai +11 more
TL;DR: Dose-dense treatment offers better survival than conventional treatment and is a potential new standard of care for first-line chemotherapy for patients with advanced epithelial ovarian cancer.
Journal ArticleDOI
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Aikou Okamoto,Takashi Nikaido,Kazunori Ochiai,Satoshi Takakura,Misato Saito,Yuko Aoki,Nobuya Ishii,Nozomu Yanaihara,Kyosuke Yamada,Osamu Takikawa,Rie Kawaguchi,Seiji Isonishi,Tadao Tanaka,Mitsuyoshi Urashima +13 more
TL;DR: The indoleamine 2,3-dioxygenase screened with the GeneChip was positively associated with paclitaxel resistance and with impaired survival in patients with serous-type ovarian cancer.
Journal ArticleDOI
A Novel Gene, CRR9, Which Was Up-Regulated in CDDP-Resistant Ovarian Tumor Cell Line, Was Associated with Apoptosis
TL;DR: Transfection assay showed that the CDDP-sensitive strain 2008 with CRR 9 was more sensitive to CDDP, indicating that CRR9 was not associated with theCDDP-resistance, but the CD DP-induced apoptosis.
Journal ArticleDOI
Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial
Toru Sugiyama,Aikou Okamoto,Takayuki Enomoto,Tetsutaro Hamano,Eriko Aotani,Yasuhisa Terao,Nao Suzuki,Mikio Mikami,Nobuo Yaegashi,Kiyoko Kato,Hiroyuki Yoshikawa,Yoshihito Yokoyama,Hiroshi Tanabe,Koji Nishino,Hiroyuki Nomura,Jae Weon Kim,Byoung-Gie Kim,Byoung-Gie Kim,Sandro Pignata,Jérôme Alexandre,John Green,Seiji Isonishi,Fumitoshi Terauchi,Keiichi Fujiwara,Daisuke Aoki +24 more
TL;DR: No significant survival benefit was found for CPT-P in patients with CCC, and both regimens were well tolerated, but the toxicity profiles differed significantly.